PARNF News and Press, Parnell Pharmaceuticals Holdings Ltd. From 12/23/19

Parnell Pharma ( OTCPK:PARNF ): 9M net loss of A$1.38M More news on: Parnell Pharmaceuticals Holdings Ltd, Earnings news and commentary, , Read more ...

Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results. SYDNEY, AUSTRALIA / ACCESSWIRE / December 23, 2019 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF) today a...

Parnell announces a new contract manufacturing agreement for one animal health product and a memorandum of understanding for two additional products with a global multi-national; revenue in the first half of 2019 down 12% compared to 2018 due to timing of technology transfer revenues versus ...

Parnell Pharma ( OTCPK:PARNF ): Q1 net loss of A$3.05M More news on: Parnell Pharmaceuticals Holdings Ltd, Earnings news and commentary, , Read more ...

Parnell Delivers 9% Revenue Growth in Quarter 1 of 2019 Compared to 2018, and Confirms Provisional 2019 Guidance for a 17 - 25% Increase Over 2018 Revenue to $31 - $33 Million and an EBITDA Range of $7.5 - $8.5 Million Subject to Winning at Least One New Contract Manufacturing Agreement in 2...

SYDNEY, AUSTRALIA / ACCESSWIRE / April 30, 2019 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General M...

Parnell Pharma ( OTCPK:PARNF ): FY Net profit of A$0.13M. Revenue of A$26.54M (+38.8% Y/Y) Press Release More news on: Parnell Pharmaceuticals Holdings Ltd, Earnings news and commentary, ,

Parnell Delivers 39% Revenue Growth and a $6.5 Million Improvement in EBITDA in 2018 Compared to 2017, Returns to NPAT Profitability, and Provides Provisional 2019 Guidance For a 17 - 25% Increase Over 2018 Revenue to $31 - $33 Million and an EBITDA Range of $7.5 - $8.5 Million. SYDNEY, ...

MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and ...